Original research

Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features

George E Fragoulis , Jonathan Cavanagh, Alistair Tindell, Mohammad Derakhshan , Caron Paterson, Duncan Porter, Iain B McInnes , Stefan Siebert

To cite: Fragoulis GE, Cavanagh J, Tindell A, *et al.* Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. *RMD Open* 2020;**6**:e001376. doi:10.1136/rmdopen-2020-001376

► Supplemental material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2020-001376>).

Received 23 June 2020
Revised 12 August 2020
Accepted 23 September 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

Correspondence to

George E Fragoulis; gefragoulis@yahoo.gr; George.Fragoulis@glasgow.ac.uk

ABSTRACT

Objective Depression and anxiety are not uncommon in Rheumatoid arthritis (RA). It is increasingly recognised that they are associated with high disease activity and worse disease outcomes. We aimed to examine the frequency of depression and anxiety in an early RA inception cohort and to explore associations with disease-related measures.

Methods The Scottish Early Rheumatoid Arthritis inception cohort recruited newly diagnosed RA patients followed-up 6-monthly. Anxiety and depression were assessed using the hospital anxiety and depression scale. Associations with demographic characteristics and disease-related measures were examined at baseline, 6 months and 12 months.

Results 848 RA patients were included. The prevalence of anxiety and depression at baseline was 19.0% and 12.2%, respectively. Depression and anxiety scores correlated with DAS28 at all time-points (all $p < 0.0001$). In multivariable linear regression, anxiety score at baseline was associated with younger age and Health Assessment Questionnaire (HAQ) score. Anxiety scores at 6 months and 12 months were associated with low body mass index (BMI), baseline anxiety score and current patient global score and HAQ. Depression score at baseline was associated with younger age, being single and HAQ, while depression scores at 6 months and 12 months were associated with male gender (only at 6 months), baseline anxiety and depression scores and current patient global score, HAQ and C-reactive protein (CRP) levels.

Conclusion Depression and anxiety are associated with disease activity, worse functional status and other variables in early RA. There is a close relationship between CRP and depression but not anxiety.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory arthritis with both musculoskeletal and systemic features. RA is associated with several physical (eg, cardiovascular) and psychological comorbidities and it is increasingly recognised that depression and anxiety are associated with high disease activity, worse disease outcomes and decreased quality of life.^{1–6} Most studies

Key messages

What is already known about this subject

- Depression is not uncommon in rheumatoid arthritis (RA).
- Depression is associated with disease activity and worse disease outcomes in established RA.

What does this study add

- There is a close relationship of CRP with depression in RA.
- In early RA, depression and anxiety are common, display an improving trend over time and associate with disease activity and worse functional status and outcome.

How might this impact on clinical practice or future developments?

- Clinicians should be aware that anxiety and depression are common in early RA and that while treating RA properly appears to help anxiety and depression, this may not be sufficient.

investigating the association of RA with depression and anxiety are cross-sectional and performed in patients with established RA of several years' duration^{2–4} and/or in patients having received treatment for RA.^{1–3} The frequency and relationship of psychological factors in early RA has been less studied and may differ from established RA. Here, we examine longitudinally the frequency of depression and anxiety in a large inception cohort of early RA patients and the relationship with demographic characteristics and disease-related measures.

METHODS

Cohort description

The Scottish Early Rheumatoid Arthritis (SERA) inception cohort⁷ prospectively recruited patients with new-onset RA (ACR-EULAR 2010 criteria) presenting to secondary-care rheumatology centres across Scotland

between 2011 and 2015. Participants were treated by their usual rheumatology team as per standard clinical practice. Assessments were recorded at the baseline visit (within 6 months of their diagnosis) and then at 6 months and 12 months follow-up visits. A range of pre-specified features were recorded at the baseline visit and then at 6-monthly follow-up visits. These included demographic (age, gender, body mass index (BMI), current alcohol consumption, smoking, employment and marital status), clinical (tender and swollen joint counts, patient global assessment visual analogue scale (PGA-VAS) for disease activity, treatment being received), laboratory (Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP), Rheumatoid factor (RF) and anti-cyclic citrullinated peptides (anti-CCP) status) parameters and disease-related indices (Disease activity score-28 (DAS28) and Health Assessment questionnaire (HAQ)—higher HAQ meaning greater disability). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/patients were approved by the West of Scotland Research Ethics Committee (Reference 10/S0704/20). Written informed consent was obtained from all participants.

Study design

The Hospital Anxiety and Depression Scale (HADS) was completed by SERA participants at each visit. As has been previously suggested,⁸ anxiety and depression were analysed separately each having a score between 0 and 21. The 'change' of various scores and parameters (depression score, anxiety score, DAS28, CRP) was the difference between final and baseline values. Results were analysed as continuous variables except when determining the frequency of depression or anxiety. For these, variables were analysed as categorical, using established cut-off scores of ≥ 11 for probable cases of anxiety and/or depression.⁸ HADS was also recorded for age-matched and sex-matched individuals ($n=58$) with similar genetic background who were included as healthy volunteers in SERA cohort. As previously described,⁷ these were friends of relatives of the RA patients participated in the study.

Statistics

Univariable analyses were performed at baseline, 6 months and 12 months. Two-sided Fisher's exact and Mann-Whitney U tests were used to compare categorical and continuous characteristics, respectively. Wilcoxon matched paired test was used for paired continuous observations. Spearman's rank correlation coefficient was used for correlations. Benjamini-Hochberg correction was applied for multiple-comparison correction for a false discovery rate of 0.25. Cronbach's alpha test was used to measure internal consistency for depression and anxiety scales. Multivariable linear regression was performed using the anxiety and depression scores as

dependent variables, and as independent variables the features recorded for the participants (see cohort description). These were: demographic (age, gender, BMI, alcohol consumption, smoking, employment and marital status), clinical (tender and swollen joint counts, PGA-VAS, treatment received), laboratory (RF status, anti-CCP status, ESR and CRP) and disease-related indices (HAQ). For depression and anxiety scores at 6 months and 12 months, baseline depression and anxiety scores were also used as independent variables. Collinearity diagnostics, calculating variance inflation factor, were run for all models. Independence of observations were checked using Durbin-Watson test. Homoscedasticity was also checked. Statistical analysis was performed using GraphPad Prism 5.00 (Inc. La Jolla, CA, USA) and SPSS 21.0 (Armonk, NY: IBM Corp, USA).

RESULTS

Patient characteristics

Data from 848 patients with RA were available for evaluation at baseline. Most of the patients (70.0%) were females and their mean $\pm$ SD age was of 58.27 $\pm$ 13.71 years. Their mean $\pm$ SD DAS28, at baseline, was 4.95 $\pm$ 1.41. Baseline characteristics and treatment received for RA during the first 12 months of follow-up time are presented in [table 1](#). At baseline, 81 patients were already treated with psychotropic drugs (eg, serotonin-norepinephrine reuptake inhibitors). During the first 6 and 12 months of follow-up, only 10 and 4 additional patients were commenced on medication for mood disorders.

At 6 months and at 12 months, 691 and 618 RA participants, respectively, were available for evaluation. Comparing participants who continued their follow-up and those who did not, at the 6-month and/or 12-month time-points, there were no significant differences in either the percentages of patients with baseline anxiety or depression (at 6 months; anxiety: $p=0.736$, depression: $p=0.178$ and at 12 months; anxiety: $p=0.168$, depression $p=0.157$) or in the baseline anxiety or depression scores.

Prevalence of anxiety and depression over time

Frequency of anxiety and depression at baseline in early RA were higher than in healthy individuals (anxiety: 19.0% vs 1.7%, $p=0.0002$; depression: 12.2% vs 1.7%, $p=0.009$) and displayed an improving trend, over time. In fact, prevalence of anxiety and depression at 6 months was 15% and 9.7% and at 12 months, 13.4% and 8.1%, respectively ([figure 1A](#)). Anxiety and depression HADS scores were also highest at baseline and were decreased at 6 months and 12 months. Median (interquartile range—IQR) scores at baseline, 6 months and 12 months for anxiety were: 6.0 (3.0–9.0), 5.0 (2.0–8.0), 4.0 (1.8–8.0), respectively, and for depression were: 5.0 (2.0–8.0), 3.0 (1.0–7.0) and 3.0 (1.0–6.0), respectively. All Wilcoxon matched paired tests (6 months and 12 months, compared to baseline) are statistically significant ($p<0.0001$) ([figure 1B,C](#)). Separate subgroup analysis of the 81

Table 1 Baseline characteristics of the rheumatoid arthritis patients included in the analysis

Characteristic	n=848
Demographic	
Age (years) (mean±SD)	58.27±13.71
Female gender, n (%)	594 (70.0)
Smoking (current), n (%)	232 (27.4)
Alcohol consumption (current), n (%)	477/836 (57.1)
Weight (kg), (mean±SD)	78.14±17.13
Body Mass Index (kg/m ²), (mean±SD)	28.25±5.76
Unemployment, n (%)	55 (6.5%)
Clinical	
Tender Joints, median (IQR)	7 (1–11)
Swollen joints, median (IQR)	6 (1–14)
Patient's global assessment (0–100 mm), (mean±SD)	52.7±27.6
DAS28-ESR, (mean±SD)	4.95±1.41
DAS28-CRP (mean±SD)	4.86±1.33
Anxiety baseline (0–21), median (IQR)	6.0 (3.0–9.0)
Anxiety score ≥11, n (%)	161 (19.0)
Depression baseline (0–21), median (IQR)	5.0 (2.0–8.0)
Depression score ≥11, n (%)	103 (12.2)
Laboratory	
RF positive, n (%)	348/541 (64.3)
Anti-CCP positive, n (%)	496/713 (69.6)
ESR (mm/hr), (mean±SD)	31.2±24.3
CRP (mg/l), (mean±SD)	26.5±35.5
Treatment*	
Methotrexate, n (%)	596/699 (85.3)
Sulfasalazine, n (%)	337/699 (48.2)
Hydroxychloroquine, n (%)	336/699 (48.1)
Leflunomide, n (%)	5/699 (0.71)
Steroids, by mouth, n (%)	61/699 (8.7)
Steroids, intramuscularly, n (%)	515/699 (73.7)
Biologic drugs, n (%)	32/699 (4.6)

*Treatment received during the 12 months follow-up time. n, number; Kg, kilogram; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; mm, millimetres; hr, hour; CCP, citrullinated peptide; mg, milligrams; l, litre.

patients who were already treated with psychotropic drugs at baseline indicated that the improving trend for both anxiety and depression was also observed in this group. However, statistical significance was only reached for comparisons between baseline and 12 months (online supplemental figure 1). In general, the internal consistency of the anxiety and depression scales was good. Cronbach's alpha at baseline, 6 months and 12 months for depression were: 0.834, 0.860 and 0.855, and for anxiety were: 0.865, 0.888 and 0.892, respectively.

Association of anxiety and depression with RA disease activity

Anxiety and depression scores were significantly positively correlated with DAS28 disease activity scores at all time-points (online supplemental figure 2). Correlations were

weaker for anxiety compared to those observed for depression scores. In detail, results were as follows: for anxiety; baseline ($p<0.0001$, $r=0.187$), 6 months ($p<0.0001$, $r=0.299$), 12 months ($p<0.0001$, $r=0.332$) and for depression; baseline ($p<0.0001$, $r=0.333$), 6 months ($p<0.0001$, $r=0.401$), 12 months ($p<0.0001$, $r=0.454$). A separate analysis examining the association between anxiety and depression scores with disease activity in the subgroup of patients who were already on treatment with psychotropic drugs at baseline ($n=81$) showed similar findings.

Furthermore, baseline anxiety and depression scores correlated with DAS28 scores at 6 months and 12 months (online supplemental figure 3). For baseline anxiety; 6 months ($p<0.0001$, $r=0.230$), 12 months ($p<0.0001$, $r=0.217$) and for baseline depression; 6 months ($p<0.0001$, $r=0.265$), 12 months ($p<0.0001$, $r=0.217$). Change (final–baseline values) in the anxiety and depression scores of the patients correlated with change in DAS28 scores at both 6 months and 12 months (online supplemental figure 4). For anxiety; 0–6 months ($p=0.001$, $r=0.160$), 0–12 months ($p<0.0001$, $r=0.255$) and for depression; 0–6 months ($p<0.0001$, $r=0.291$), 0–12 months ($p<0.0001$, $r=0.368$). It should be noted that correlation of change in anxiety scores with changes in DAS28 at 6 months was relatively weak.

Associations with demographic, clinical and biochemical measures of RA

The demographic, clinical and biochemical features associated with anxiety and depression in the univariable analyses, at the three time-points examined, are presented in tables 2 and 3.

Notably, analysing further the association of CRP with depression (but not anxiety) at all time-points, we found that change (final–baseline values) in CRP levels also correlated with change in depression scores at all time-points (0–6 months; $P<0.0001$, $r=0.185$ and 0–12 months; $P<0.0001$, $r=0.302$).

Multivariable linear regression analysis largely confirmed results from univariable analyses and are presented in table 4 (only parameters that were statistically significant for at least one time-point are presented). The anxiety score at baseline was correlated with younger age and HAQ score (higher HAQ meaning greater disability). At 6 months and 12 months, the anxiety score was associated with baseline anxiety score, lower BMI and higher current HAQ score and PGA-VAS score. The depression score at baseline was also associated with younger age, HAQ and additionally with being single. At 6 months and 12 months, the depression score was associated with baseline depression and anxiety scores as well as with male gender (only at 6 months), current PGA-VAS scores, HAQ scores and CRP levels.

DISCUSSION

Depression and anxiety are important comorbidities in RA and are associated with less favourable disease outcomes

Figure 1 (A) Prevalence of anxiety and depression measured by hospital anxiety and depression scale (HADS) in early rheumatoid arthritis over time from baseline (cut-off ≥ 11 for both). Longitudinal HADS anxiety (B) and depression (C) scores. Bars and lines represent mean and SEM, respectively. All Wilcoxon matched paired test (6 months and 12 months, compared to baseline are statistically significant, $p < 0.0001$).

and reduced quality of life. The prevalence of depression in our cohort was 13%. The reported frequency of depression in published RA studies ranges between 13% and 56%.^{9 10} However, investigators examining psychological comorbidities in RA have used different tools to assess this, making it difficult to compare between studies. Our study used HADS, which is highly reliable in the detection of depression in RA.¹¹ A meta-analysis estimated that depression, measured by HADS, occurred in 14.8% of RA patients.¹⁰ Anxiety is even more frequent than depression in both our cohort (19%) and the published literature (25–46%).^{1 3}

It is generally recognised that depression and anxiety scores in RA decrease over time, which was also observed in our cohort over the first 12 months following diagnosis.^{12 13} The reasons for this are currently unclear but several parameters (eg, better control of RA, less inflammation) might contribute. As also observed in our study, depression score is associated with RA disease activity,¹³ although the direction of this relationship has not been defined¹⁴ and causality cannot be inferred from observational studies. Of note, correlations between disease activity and anxiety scores were weaker compared to that recorded for depression scores.

Several studies report that baseline depression and anxiety levels in RA are associated with decreased likelihood of achieving remission,^{1 3 4} although others have not found this.² On the other hand, studies in early RA report that higher joint counts at baseline are associated with increased depression at month 6.¹³ Another study suggested that the HAQ score was the most important predictor of psychological stress in early RA,¹² with a variety of other demographic and socio-economical features like occupation and family income to be associated with depression and anxiety in RA.¹² In our study, univariate analyses identified a number of factors associated with HADS anxiety or depression scores at all time-points including baseline depression and anxiety scores, unemployment, being single, younger age, HAQ score and increased disease activity measures.

Multiple linear regression analysis indicated that current HAQ scores and baseline depression and anxiety scores were the strongest predictors of depression and

anxiety scores. The association between HAQ and depression is consistent with findings from another study using data from SERA cohort, which reported that functional disability at 1-year after RA diagnosis was predicted by depression and anxiety among other factors.¹⁵ Similarly, another study examining predictors of depression in a multi-ethnic RA cohort showed that higher HAQ scores were associated with depression.⁹ Furthermore, in the multivariable analysis in our study, CRP and PGA-VAS were the only measures of disease activity assessed by DAS28 associated with depression.

Notably, CRP was associated with depression but not anxiety at all time-points in univariate analysis and at 6 months and 12 months in the multivariable analysis, suggesting a close relationship between inflammation and depression. This is consistent with a previous cross-sectional study, which reported that CRP was significantly correlated with depression levels in RA.¹⁶ Another study of RA patients with $\text{DAS28} \geq 3.2$ and disease duration between 3 months and 2 years reported higher CRP levels at baseline in patients who had depression compared to those who did not.¹

There appears to be a complex interplay between depression and RA, with shared inflammatory pathways postulated.¹⁷ It has been suggested that the aberrant immune responses in RA could cause alterations in the central nervous system via neuronal and humoral pathways.¹⁷ Notably, Schrepf *et al*¹⁸ have demonstrated how chronic inflammation in RA has an impact on the brain. Higher peripheral inflammation was consistently correlated with neural connectivity patterns, particularly inferior parietal lobule and medial prefrontal cortex over a 6-month period. The RA-depression immunobiological axis is evidenced by various data. For example, in RA blockade of systemic TNF has beneficial effects on centrally mediated behaviours including mood.¹⁹ Further, anti-TNF therapy in RA acutely alters fMRI brain activation.^{20 21} This aligns with significant overall improvement in well-being, which patients can report often in advance of any objective improvement in their peripheral joint inflammation for example, swollen joints. Said that,

Table 2 Univariable analysis. Variables associated with anxiety and/or depression scores at baseline, month 6 and month 12. All variables are at baseline unless otherwise indicated by †. Significant values are highlighted in bold

Anxiety score

	Baseline		6 months		12 months	
Categorical factors	P value		P value		P value	
Female gender	0.002		0.212		0.214	
Smoking	0.124		0.008		0.039	
Unemployment*	0.001		<0.0001		<0.0001	
Marital status†	0.04		0.004		0.01	
Continuous variables	R	P value	r	P value	r	P value
Age	−0.187	<0.0001	−0.158	<0.0001	−0.131	0.001
BMI	0.005	0.897	−0.044	0.289	−0.084	0.044
Anxiety baseline	NA	NA	0.691	<0.0001	0.632	<0.0001
Depression baseline	0.681	<0.0001	0.507	<0.0001	0.443	<0.0001
Tender joint count (0–28)‡	0.169	<0.0001	0.314	<0.0001	0.306	<0.0001
Swollen joint count (0–28)‡	0.011	0.759	0.161	<0.0001	0.184	<0.0001
Patient global VAS‡,¶	0.210	<0.0001	0.397	<0.0001	0.387	<0.0001
HAQ¶	0.339	<0.0001	0.409	<0.0001	0.446	<0.0001

Depression score

	Baseline		6 months		12 months	
Categorical factors	P value		P value		P value	
Smoking	0.343		0.021		0.002	
Unemployment	0.001		<0.0001		<0.0001	
Marital status	0.008		0.007		0.03	
Anti-CCP negative	0.013		0.431		0.900	
Glucocorticoids	NA		0.017**		0.005††	
Continuous variables	R	P value	r	P value	r	P value
Age	−0.101	0.004	−0.028	0.494	−0.012	0.770
BMI	0.075	0.037	0.051	0.224	0.058	0.183
Alcohol units§	−0.107	0.002	−0.037	0.332	−0.057	0.160
Anxiety baseline	0.681	<0.0001	0.488	<0.0001	0.423	<0.0001
Depression baseline	NA	NA	0.602	<0.0001	0.519	<0.0001
Tender joint Count (0–28)‡	0.263	<0.0001	0.361	<0.0001	0.388	<0.0001
Swollen joint Count (0–28)‡	0.117	0.0007	0.265	<0.0001	0.276	<0.0001
Patient global VAS‡	0.328	<0.0001	0.500	<0.0001	0.522	<0.0001
HAQ¶	0.541	<0.0001	0.594	<0.0001	0.609	<0.0001
ESR¶	0.116	0.016	0.077	0.128	0.130	0.029
CRP¶	0.163	<0.0001	0.152	<0.0001	0.112	0.004

*ANOVA test, reference group employed and retired individuals.

†Married or living with partner compared to individuals who are single.

‡Used for DAS28 calculation.

§Average alcohol units/week.

¶At time point of interest.

**Oral.

††Intramuscular. BMI, body mass index; NA, not applicable; CCP, cyclic citrullinated peptide; DAS, disease activity score; VAS, visual analogue scale; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. Benjamini-Hochberg correction did not affect the statistical significance of the reported values at any of the time-points examined. See table 3 for more details about categorical variables.

as mentioned earlier, in the multiple regression analysis of our study, depression was associated with CRP and PGA-VAS but not with tender or swollen joints count. Our data, especially those showing the

relationship between CRP and depression over time support this peripheral blood-neural network link in RA. It also provides a supportive perspective on the increasingly compelling data implicating the immune-

Table 3 Anxiety and depression scores for categorical variables presented in table 2

Anxiety			
Factors	Baseline	6 months	12 months
	mean±SD	mean±SD	mean±SD
Female/Male	6.8±4.3/5.6±4.5	5.7±4.4/5.4±4.6	5.3±4.4/4.7±4.3
Smokers/Non-smokers	6.8±4.5/6.3±4.4	6.4±4.8/5.3±4.3	5.9±4.7/4.9±4.2
Unemployed/Employed or Retired	9.1±5.0/6.4±4.4 or 5.9±4.2	8.6±5.7/5.6±4.2 or 5.0±4.3	8.6±5.6/5.1±4.2 or 4.7±4.2
Married-partner/single	6.1±4.2/6.9±4.7	5.2±4.1/6.5±5.0	4.8±4.1/5.9±4.8
Depression			
Factors	Baseline	6 months	12 months
	mean±SD	mean±SD	mean±SD
Smokers/Non-smokers	5.8±3.8/5.5±3.9	5.2±4.1/4.4±3.8	5.2±4.2/3.9±3.6
Unemployed/Employed or Retired	7.7±4.6/5.6±3.9 or 5.3±3.7	7.5±4.4/4.3±4.0 or 4.4±3.4	7.9±5.1/3.9±3.8 or 4.0±3.4
Married-partner/single	5.3±3.5/6.3±4.4	4.3±3.8/5.2±4.2	4.0±3.6/4.8±4.0
Anti-CCP (-)/Anti-CCP (+)	6.20±3.98/5.39±3.72	4.7±3.8/4.5±3.9	4.2±3.8/4.2±3.8
Glucocorticoids (Yes/No)	NA	5.3±3.9/4.4±3.9	4.4±3.9/3.4±3.5

Statistically significant differences are shown in bold. Respective p values are presented in table 2.

Table 4 Multivariable linear regression analysis. Variables associating with high anxiety and/or depression scores at baseline, month 6 and month 12. All variables at baseline unless otherwise indicated by ‡

Anxiety score						
Covariates	Baseline		6 months		12 months	
	P value	Beta	P value	Beta	P value	Beta
Age	0.001	-0.217	0.669	-0.024	0.960	-0.003
BMI	0.669	-0.020	0.015	-0.097	0.001	-0.141
Anxiety baseline	NA	NA	<0.0001	0.609	<0.0001	0.555
Patient global VAS*†‡	0.261	0.061	0.008	0.135	0.009	0.139
HAQ‡	<0.0001	0.307	0.006	0.146	0.001	0.208
Depression score						
Covariates	Baseline		6 months		12 months	
	P value	Beta	P value	Beta	P value	Beta
Age	0.029	-0.128	0.477	0.039	0.108	-0.074
Gender	0.392	0.039	0.016	-0.689	0.153	-0.436
Marital status†	0.022	0.097	0.974	-0.001	0.716	0.015
Baseline depression score	NA	NA	<0.0001	0.352	<0.0001	0.303
Baseline anxiety score	NA	NA	0.002	0.165	0.04	0.121
Patient global VAS‡	0.101	0.082	0.012	0.125	0.010	0.136
HAQ‡	<0.001	0.486	<0.0001	0.327	<0.0001	0.372
CRP levels‡	0.508	0.034	0.009	0.133	0.003	0.151

*Used for DAS28 calculation.

†Married or living with partner compared to individuals who are single.

‡At time point of interest. BMI, body mass index; NA, not applicable; VAS, visual analogue scale; HAQ, health assessment questionnaire; CRP, C-reactive protein.

Significant values are shown in bold.

inflammatory response in some aspects of the pathophysiology of mental disorders¹⁷ notably major depressive disorder.^{22–24}

Herein, we show, as previously reported,¹³ that anxiety is highly prevalent in early RA. In our study, patient global

VAS correlated with anxiety levels, which could partially explain the association between anxiety and worse disease activity outcomes in RA.²⁵ However, in contrast to what we observed for depression in our cohort (as outlined above), anxiety was not associated with CRP, neither in

univariate nor in multivariable analysis. The reasons for this are not clear and merit further investigation. It should also be noted that 'anxiety' encompasses a heterogeneous spectrum of symptoms, ranging from contextual physiological anxiety through to anxiety disorders,²⁶ with some but not others associated with some degree of inflammation.²⁷ A more focused analysis might reveal whether there is an 'anxiety phenotype' in RA that is possibly linked with inflammation.

The inverse correlation between BMI and anxiety (but not depression) levels at 6 and 12 months in our study is not surprising, considering that large population studies have shown a U-shape relationship between anxiety and BMI.²⁸ Data from the Rochester Epidemiology Project indicate that anxiety is increased in underweight and obese, but not overweight, people. This association was more pronounced in females.²⁸ Finally, in our early RA cohort, baseline anxiety levels were found to be significantly associated with subsequent anxiety scores, highlighting that anxiety should also be considered in the treatment plan of patients with RA, from the early stages of disease.

Many studies examining psychological comorbidities in RA typically focus on depressive symptomatology and disregard anxiety or describe the psychological burden without distinguishing between depression and anxiety. However, as shown here, there are differences between depression and anxiety, at least in terms of the associating factors in RA, further reinforcing the notion that they should be assessed separately.

We acknowledge that our study has certain limitations. First, consistent with the design of this inception cohort, no data are available for depression, anxiety or disease activity at time-points between baseline and the 6 months and 12 months visits. Given the stable trend of our results, we speculate that it is unlikely that an important finding would have been missed. Similarly, limited data were available for patients followed-up for a longer time period. These, however, are continuously recorded and will be analysed in future studies. Furthermore, the number of healthy individuals is small compared that of RA patients and there may be some differences in the performance of the HADS questionnaire between healthy and RA individuals. Therefore, the differences between these two groups should be interpreted with caution. Finally, although some of the findings have been shown by other studies as well, our early RA inception cohort is one of the largest, examining longitudinally mental health disorders, with a validated tool in these patients.

In conclusion, our study indicates that clinicians should be alert to neuro-psychiatric comorbidity in RA from the earliest stages of the disease when the prevalence and levels of depression and anxiety appear to be highest. While depression and anxiety have been shown to have a negative impact on outcomes in RA, it remains to be determined whether more intense screening and treatment for psychiatric comorbidities, especially in some subgroups of patients (eg, those with high CRP, high

HAQ scores) can improve outcomes. Our results also highlight again the link between inflammation and depressive symptomatology. The intertwining of these conditions points to potential common pathophysiology thus opening the possibility of greater mechanistic understanding and thus greater therapeutic opportunity.

Acknowledgements We would like to thank SERA investigators for their contribution in data collection.

Contributors GEF: drafting the manuscript, data analysis, data collection. JC: drafting and critically revising the manuscript. AT: drafting the manuscript, data analysis, data collection. MHD: drafting the manuscript, statistical analysis. CP: drafting the manuscript, data collection. DP: data collection, critically revising the manuscript, inception of the study. IBM: data collection, critically revising the manuscript, inception of the study. SS: data collection, drafting and revising the manuscript, inception of the study.

Funding The SERA cohort was supported by joint funding from the Chief Scientist's Office (award ref ETM-40) and Pfizer.

Competing interests None declared.

Patient consent for publication Written informed consent was obtained from all participants.

Ethics approval All procedures involving human subjects/patients were approved by the West of Scotland Research Ethics Committee (Reference 10/S0704/20).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

George E Fragoulis <http://orcid.org/0000-0003-4932-7023>

Mohammad Derakhshan <http://orcid.org/0000-0002-2549-7100>

Iain B McInnes <http://orcid.org/0000-0003-4449-8501>

REFERENCES

- 1 Kekow J, Moots R, Khandker R, *et al*. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. *Rheumatology (Oxford)* 2011;50:401–9.
- 2 Matcham F, Ali S, Irving K, *et al*. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. *BMC Musculoskelet Disord* 2016;17:155.
- 3 Matcham F, Norton S, Scott DL, *et al*. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. *Rheumatology (Oxford)* 2016;55:268–78.
- 4 Michelsen B, Kristianslund EK, Sexton J, *et al*. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. *Ann Rheum Dis* 2017;76:1906–10.
- 5 Kuijper TM, Luime JJ, Xiong H, *et al*. Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis

- patients over time: response data from the tREACH study. *Scand J Rheumatol* 2018;47:178–84.
- 6 Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. *Curr Psychiatry Rep* 2008;10:258–64.
 - 7 Dale J, Paterson C, Tierney A, et al. The Scottish Early Rheumatoid Arthritis (SERA) study: an inception cohort and biobank. *BMC Musculoskelet Disord* 2016;17:461.
 - 8 Snaith RP. The hospital anxiety and depression scale. *Health Qual Life Outcomes* 2003;1:29.
 - 9 Margaretten M, Yelin E, Imboden J, et al. Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. *Arthritis Rheum* 2009;61:1586–91.
 - 10 Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology (Oxford)* 2013;52:2136–48.
 - 11 Covic T, Pallant JF, Tennant A, et al. Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D scales. *BMC Musculoskelet Disord* 2009;10:18.
 - 12 Bacconnier L, Rincheval N, Flipo RM, et al. Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. *Rheumatology (Oxford)* 2015;54:520–7.
 - 13 Overman CL, Bossema ER, van Middendorp H, et al. The prospective association between psychological distress and disease activity in rheumatoid arthritis: a multilevel regression analysis. *Ann Rheum Dis* 2012;71:192–7.
 - 14 Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. *Rheumatology (Oxford)* 2013;52:1785–94.
 - 15 Kronisch C, McLernon DJ, Dale J, et al. Brief report: predicting functional disability: one-year results from the scottish early rheumatoid arthritis inception cohort. *Arthritis Rheumatol* 2016;68:1596–602.
 - 16 Kojima M, Kojima T, Suzuki S, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. *Arthritis Rheum* 2009;61:1018–24.
 - 17 Nerurkar L, Siebert S, McInnes IB, et al. Rheumatoid arthritis and depression: an inflammatory perspective. *Lancet Psychiatry* 2019;6:164–73.
 - 18 Schrepf A, Kaplan CM, Ichesso E, et al. A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis. *Nat Commun* 2018;9:2243.
 - 19 Deb A, Dwibedi N, LeMasters T, et al. Tumor necrosis factor inhibitor therapy and the risk for depression among working-age adults with rheumatoid arthritis. *Am Health Drug Benefits* 2019;12:30–8.
 - 20 Fuggle NR, Howe FA, Allen RL, et al. New insights into the impact of neuro-inflammation in rheumatoid arthritis. *Front Neurosci* 2014;8:357.
 - 21 Rech J, Hess A, Finzel S, et al. Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis. *Arthritis Rheum* 2013;65:325–33.
 - 22 Chamberlain SR, Cavanagh J, de Boer P, et al. Treatment-resistant depression and peripheral C-reactive protein. *Br J Psychiatry* 2019;214:11–19.
 - 23 Leighton SP, Nerurkar L, Krishnadas R, et al. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. *Mol Psychiatry* 2018;23:48–58.
 - 24 Cavanagh J, Paterson C, McLean J, et al. Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. *Ann Rheum Dis* 2010;69:1251–2.
 - 25 Machin AR, Babatunde O, Haththotuwa R, et al. The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis. *Clin Rheumatol* 2020;39:1471–82.
 - 26 Nandi A, Beard JR, Galea S. Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review. *BMC Psychiatry* 2009;9:31.
 - 27 Vogelzangs N, Beekman AT, de Jonge P, et al. Anxiety disorders and inflammation in a large adult cohort. *Transl Psychiatry* 2013;3:e249.
 - 28 DeJesus RS, Breitkopf CR, Ebbert JO, et al. Associations between anxiety disorder diagnoses and body mass index differ by age, sex and race: a population based study. *Clin Pract Epidemiol Ment Health* 2016;12:67–74.